My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  partner  partners  partnerships  alliance managers  ecosystem  alliance manager  The Rhythm of Business  partnership  Jan Twombly  Vantage Partners  biopharma  governance  Eli Lilly and Company  strategy  Strategic Alliance Magazine  collaborations  IBM  cloud  IoT  strategic alliances  ASAP BioPharma Conference  healthcare  innovation  Christine Carberry  Cisco 

A Swim in ‘The Aquarium:’ Your Chance to Collectively Shift the Thought Currents of Alliance Management

Posted By Cynthia B. Hanson, Wednesday, September 7, 2016

ASAP Summit and Conference participants spend a lot of time sitting, listening, and absorbing the most cutting-edge information in the industry. Now it’s your turn to be a speaker, guide, and thought provoker in a new session format at this year’s ASAP BioPharma Conference Sept. 7-9, “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed,” at the Revere Hotel Boston Common, Boston. The Aquarium session encourages attendees to dive in and wrestle with the hot topics of the day in a creative, ASAP-designed version of the “fishbowl” learning activity. Moderated by Jan Twombly, CSAP, president of The Rhythm of Business, the session will start with a lively exchange on key topics from several experts in the field of alliance management as the audience peers into the tank. There will be three 25-minute rounds during the session, each with a separate topic. Participants will be allowed to “tap in” and move the conversation in new directions. When someone comes onto the stage, one person must exit. 

“We’re not sticking to a script; each of these topic discussion could branch off,” explains Ann Johnson, ASAP’s content manager, who has developed the concept as an innovation ASAP programming.  “That’s the beauty of nontraditional session structure like this: It allows for free-space that often results in exploring topics in real and meaningful ways … through many different lenses. It encourages engagement, peer-to-peer sharing, and participation, which is what our members want. There are no right answers to these topics, and in fact we want to hear diverse viewpoints,” Johnson adds. “This is a way to hear from the voices we often don’t hear from.” 

It’s an opportunity to become a member of the “school” in a fast-paced, collective swim that is geared to leave participants with a more creative and innovative perspective on the potential for change in alliance management. The following preselected topics are designed to jumpstart the conversation:

Topic #1: Lead, Follow, or Get Out of the Way

True or False: The alliance management profession in biopharma has the respect, skills, and ability to lead companies into partnering with different types of partners, across industries, and in new models.

Topic #2: Handle with Care: Managing the C-Suite

How do you ensure executive leadership (C-Suite) is appropriately involved in an alliance, without giving them a seat at the table, especially when the alliance is between a small, innovative company and big pharma?

Topic #3: Breadth or Depth – What Does it Take to Succeed?

Which qualities will be more highly valued in alliance managers as the industry adapts to digitization, outcomes based pricing, and an increasing number and variety of partnerships: broad business and technical skills and experience or deep pharmaceutical industry knowledge and experience?

As the conversation evolves, participants will then get a chance to bump the following thought leaders and senior-level partnering executives off the stage: 

  • Jeremy Ahouse, CSAP, PhD, Executive Director Alliance Management, Celgene
  • Harm-Jan Borgeld, CSAP, PhD, Head Alliance Management, Merck Serono 
  • David Burnham, Senior Vice President Strategic Alliance Management, INC Research
  • Mark Coflin, CSAP, Senior Director Alliance Management Global BD&L, Baxalta US Inc.  
  • Cathy Connelly, CA-AM, Head, Alliance Management, Sanofi Genzyme
  • Andy Hull, CA-AM, Vice President, Global Alliances, Takeda Pharmaceuticals
  • Katherine Kendrick, CA-AM; Director of Alliance Management, Elanco, Eli Lilly and Company
  • Brooke A. Paige, CSAP, Staff Vice President, Strategic Initiatives, HealthCore, Inc.
  • Petra Sansom, Sr. Director, Alliance Management, Vertex Pharmaceuticals
  • Mary Jo Struttmann, CA-AM; Executive Director, Global Alliance Management, Astellas Pharma Inc.
  • Michael Sumpter, Head of Alliance Management, Servier Monde
  • David S. Thompson, CA-AM, Chief Alliance Officer, Eli Lilly and Company
  • Steve Twait, CSAP, VP, Alliance and Integration Management, AstraZeneca

 Photo credit:  MB Photo Credit: W. Chappell

Tags:  alliance management  alliance managers  Ann Johnson  Astellas  AstraZeneca  biopharma  c-suite  David Thompson  Eli Lilly and Company  Jan Twombly  Mary Jo Struttmann  Michael Sumpter  partnerships  Petra Sansom  pharma  Servier Monde  Steve Twait  The Rhythm of Business  Vertex Pharmaceuticals 

Share |
PermalinkComments (0)
 

Ben Gomes-Casseres and the Bayer Team Return to the 2016 ASAP BioPharma Conference with an Interactive Roundtable on Creating Alliance Success

Posted By Cynthia B. Hanson, Tuesday, September 6, 2016

One session at last year’s ASAP BioPharma Conference was such a success that Ben Gomes-Casseres, CSAP, DBA, and the Bayer HealthCare team are returning with the same theme in a new interactive roundtable format. Their deep dive on “Making Better Alliances: How Alliance Management, Business Development, and Legal Can Collaborate More Effectively” will delve into how to successful integrate alliance management, business development, and the legal division to improve alliance success rates.  They return to the stage for this year’s ASAP BioPharma Conference Sept. 7-9 “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed” at the Revere Hotel, Boston Common, Boston.

 

An alliance strategy consultant, professor at Brandeis University in Waltham, Mass., and author, Gomes-Casseres will be moderating the session with Bayer award-winning cross-functional team of John A. Calvo, Karen Denton, CA-AM, and Claudia Karnbach problem-solving an alliance management case. Attendees will be participants, too, tackling tricky alliance scenarios with best practices through dynamic peer-to-peer exchanges. I asked Gomes-Casseres a few questions about the impetus for the session.

 

What are the most common reasons for the high failure rate of alliances?

As a community, we have made great strides in alliance management, but we have been myopic. We need to broaden our view so that we can see more clearly the faults in alliance strategy and design that frequently lead to dissolution.

The reason half of all alliances fail can be largely attributed to poor up-front design, which includes: 

  • Choosing the wrong partner
  • Deciding to partner for the wrong reasons
  • Flawed contract terms

Part of the problem is that alliance management is left out of the early decision process. Part of it also is that alliance management, business development, and legal speak different languages and concerns. Making a robust alliance requires effective collaboration between business development, legal, and alliance management. However, this aspect of internal collaboration often receives less attention from alliance managers than the work they perform after the deal is “done.” That’s one component in critical need of change to improve the success rate.

What solutions will you and the Bayer panel be recommending in your session? 

At the 2015 BioPharma Conference last year, I held a session with Bayer Healthcare executives from alliance management, business development, and the legal division that focused on four areas: 

  • How Bayer’s does the “Deal to Alliance” process, which is a way of describing how to pay attention to both alliance strategy and management
  • The importance of involving alliance management early on in the deal
  • The contributions alliance management makes to negotiation and contract terms
  • How combining these elements builds more robust alliances

This year, I invited the same team that provided a session at the BioPharma Conference last year to come back and work in an interactive continuation of that session with participants. We plan to quickly rehash what was covered last year and then do a deep dive into fresh and innovative approaches. We plan to share a case study and explore in open discussion how to solve it. In the process, participants will learn how alliance management can contribute to business development and contracting and the best way to bring the D2A process back to their own companies.

 What is your goal of the session for participants?

 The goal is simple but essential to having a solid alliance. We want to:

  • Make more robust and quicker alliances
  • Resolve the differences of perspective among functions in alliance design
  • Broaden the role of alliance management in the organization

How does your new book Remix Strategy: The Three Laws of Business Combinations, published by Harvard Business Review Press, promote some of these ideas?

 Remix Strategy provides the tools to fix this problem. The solution lies in designing alliances so that they can be governed effectively to create value. I call it the “Deal to Alliance” process, which means paying attention to both alliance strategy and management. For a healthy alliance, it’s critical to integrate the process of designing and implementing alliances along their full lifecycle.

Tags:  alliance management  alliances  ASAP BioPharma Conference  Bayer HealthCare  Ben Gomes-Casseres  business development  Claudia Karnbach  collaboration  John A. Calvo  Karen Denton  Keywords: Remix Strategy  management  patner  strategy 

Share |
PermalinkComments (0)
 

Maximizing the Alliance Management and C-Suite Relationship Through the Eyes of Biopharma Conference Plenary Speaker Stéphane Thiroloix

Posted By Cynthia B. Hanson, Monday, August 1, 2016
Updated: Sunday, July 31, 2016

Stéphane Thiroloix describes himself as a “reasonable generalist,” having been involved with partnering in multiple waysfrom business development, general management, marketing, and sales to R&D and legal affairs. The CEO at Mayoly Spindler, an emerging family-owned, independent French company with a focus on gastroenterology and dermocosmetics, will present a plenary talk on The View from the C-Suite: Partnering and Alliances Today and Tomorrow,” Thursday morning, Sept. 8, during the 2016 ASAP BioPharma Conference. This year’s conference, “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed,” will be held Sept. 7-9 at the Revere Hotel in Boston. Mayoly Spindler’s revenue originates half in France and half abroad through activities in over 50 countries, mostly via local partnerships. The company’s portfolio strategy is based almost exclusively on partnering. Thiroloix provided this preview of his topic on how alliance management functions can best be viewed and leveraged by company senior leadership.

What are some of the challenges when coordinating the alliance management and C-Suite relationships?
The first challenge is simply understanding the role of alliance management. When you have skilled and proactive alliance managers, it does not take long for the C-Suite to appreciate their work and turn to them constantly. Another challenge is keeping the alliance manager in play at all times, even when a partner is tempted to take a more direct CEO-to-CEO route. While that’s a perfectly legitimate move, it’s then the CEO's responsibility to keep the alliance manager in play, even if it’s transiently unofficial. One interesting challenge is accepting contradictions from the alliance manager as they stand for partner interests. It’s easy to state and posture that the alliance manager is our partner's ambassador in our ExCom [executive committee], but when they make the partner's case in a difficult decision, we may feel a little strain as we remind ourselves that we hired them to do so and should pay attention.

Among your proposed discussion topics is the importance of establishing an alliance management function and its value to the senior executive team. Why has this become increasingly important in the new ecosystem?
The pharma model has become tremendously fragmented. When I started my professional life, large pharma companies were the norm, and they were fully integrated—from fundamental research to sales. Partnerships were the exception rather than the norm, and we relied mostly on our internal dynamics to succeed. Today, not only is there a constellation of small, ultra-specialized players, but even the large pharma players outsource vast quantities of strategic activities, including entire components of their R&D, most of their manufacturing, and frequently their commercial activity. As a result, the way we work today is intrinsically alliance-based. Additionally, it’s not about whether you're big or small. If you are a big, dominant player, there is high risk that you will be overpowering in your partnerships. Partners used to accept this because partnering with big pharma was the grail. That’s no longer the case, so big players need alliance management to maintain a healthy balance in their dealings with smaller players who have a variety of other doors to knock on. If you are a small player, you must be agile, humble, and alliance-focused in order to quickly build a strong partnering track record.

Describe some effective strategies partnering professionals can use to support the C-Suite?
A straight answer may be a little simplistic. The company (and its C-Suite), its partners and the alliance manager themselves, have a specific profile and style that may call for different approaches. The C-Suite requires a difficult balance between boring them with systematic activity reporting and appearing to withhold knowledge that provides an edge—which is unbearable to the C-Suite. What I've seen work well is to use the pace of partnership governance: at ExCom meetings before key alliance governance moments, provide relevant updates and gather C-Suite insight. That way you will not be covering all topics all the time. Make sure you share partner milestones to provide the C-Suite with opportunities to react in a constructive manner. If a partner cleared an FDA hurdle or raised capital, some C-Suite members may want to send a congratulatory note—but if you don’t point it out, they might miss the occasion. The best way to work the C-Suite is unquestionably to work more with their teams than with them. Similarly, make sure the C-Suite's personal assistants know where to find alliance reports, and develop flexibility and opportunities for them to connect with bosses whenever they need to deal with the alliance. Be ready to explain the same things again and again. And never, ever surprise them.

Tags:  alliance management  alliances  C-Suite  ecosystem  FDA  governance  Mayoly Spindler  partners  partnership  Stéphane Thiroloix 

Share |
PermalinkComments (0)
 

What’s Brewing in the 2016 Biopharma Conference Beaker? | Part 2

Posted By Cynthia B. Hanson, Wednesday, July 20, 2016
Updated: Tuesday, July 19, 2016

In a recent interview, ASAP CEO Mike Leonetti, CSAP, provided a sampling of what’s to come at the 2016 ASAP BioPharma Conference. He offered insights into the changing landscape for partnerships and how alliance managers and others need to adapt, as well as a preview of speakers and cutting edge sessions and workshops. 

What about ASAP? What’s brewing in the beaker and will be shared at the conference?

We will be unveiling, and introducing the author of, ASAP’s new study “The Economics of Alliances, Social Capital, and Alliance Performance,” which is scheduled for release after the conference as ASAP’s 6th State of Alliances study. You can read a preview of the study and view some of the research data in the upcoming Summer Strategic Alliance Magazine. Dr. Shawn Wilson, the author, has worked with ASAP to provide financial and economic return on investment (ROI) analytics that are a direct outcome of alliance/partnership management excellence.

What are some of the cutting edge, not-to-be-missed sessions you recommend?

While every session is going to be fantastic, the session that discusses digital or tech partnering capabilities, “New Partnerships between High Tech and BioPharma and the Alliance Management Practices to Support Them,” led by Russ Buchanan, CSAP, head of corporate alliances, Xerox Corporation, and “New Partnerships Between High Tech and BioPharma and the Alliance Management Practices to Support Them,” facilitated by Donna Peek, CSAP, director, partner enablement & operations at SAS Institute, will be timely. The unveiling of ASAP’s research and “Applying the Latest Alliance Management Research to Your Partnering Practice,” by Shawn Wilson, in conjunction with Stuart Kliman, CA-AM, who is presenting Vantage Partners’ research findings, should not be missed.  I think the sessions on “Strategic Perspectives on a Partnership's First 100 Days” offer a new twist on partnering with new players. Another session on partnering in China addresses the crucial need to understand and learn about that country, “A New Model for Western and Chinese Pharmaceutical Partnering,” by Brent Harvey, CA-AM, director, alliance management at Eli Lilly and Company.

Every year ASAP provides workshops for the alliance management toolbox. What’s new in the box this year?

There are several fantastic “Tools and Techniques” pre-conference workshops, the CA-AM and CSAP prep workshops, the Eli Lilly and Company “Alliance Management, Tools and Techniques, “ which never fails to draw rave reviews, as well as one from Candido Arreche, CA-AM, global director of portfolio & partner management, six sigma black belt at Xerox Worldwide Alliances, on “How to Resolve Conflict in Your Alliance.” New to ASAP is the workshop “Next Generation Alliance Management, Lean and Agile,” facilitated by Lynda McDermott, CA-AM, president of Equipro International, and Annick De Swaef, CSAP, president of Consensa, which will preview ASAP’s new corporate alliance management and certification program designed to offer a customized workshop for a company wishing to quickly add to its partnership capability and value creation.

To view the program and download brochure information, go to www. asapweb.org/biopharma.

Tags:  Alliance Management  Annick DeSwaef  Brent Harvey  Candido Arreche  certification  Consensa  digital  Donna Peek  Dr. Shawn Wilson  Eli Lilly and Company  Equipro International  Lynda McDermott  partnership  Russ Buchanan  SAS  Stuart Kliman  Vantage Partners  Xerox Worldwide Alliances 

Share |
PermalinkComments (0)
 

What’s Brewing in the 2016 Biopharma Conference Beaker? | Part 1

Posted By Cynthia B. Hanson, Tuesday, July 19, 2016

In a recent interview, ASAP CEO Mike Leonetti, CSAP, provided a sampling of what’s to come at the 2016 ASAP BioPharma Conference. He offered insights into the changing landscape for partnerships and how alliance managers and others need to adapt, as well as a preview of speakers and cutting edge sessions and workshops.  

Why is this a must-attend conference for alliance managers, CEOs, and others working in the biopharma, healthcare, and life sciences industries? 

Partnership management is changing. If they are performing their jobs the same way they were two years ago, they likely are leaving money on the table or missing great new opportunities. This year’s conference offers programming to learn how to partner in new environments, which includes tech, academic, and healthcare system partnerships. An ongoing message of the conference is to understand that the ecosystem is getting larger, and their enterprise now represents their company, partners, and the entire healthcare system. As alliance managers, we can no longer be comfortable defining our box as an asset partnership and staying there. We will limit our creation of value in our companies unless we harvest the enterprise. 

What’s new at this year’s conference? 

We are going to talk a lot about the changes in partnerships across the industry. We are not only going to talk about biopharma and healthcare, we are going to hear from people on the tech side of ASAP regarding what’s important and best practices when partnering with tech. It will provide key opportunities to learn about tech companies and how they partner. If biopharma and healthcare are going to partner with tech, each of these industries needs to have a clear understanding of the others’ expectations. 

What timely message is Dr. Samuel Nussbaum, strategic consultant at EGB Advisors, Inc., likely to provide during his keynote address? 

The keynote, “Healing the U.S. Health Care System: Collaboration is Essential,” which is scheduled for the afternoon of Wed., Sept. 7, will tie directly into our theme. Sam is going to talk about his background and expertise with the impact of public policy on healthcare systems and healthcare reform. He will talk a lot about how important collaboration is to finding a solution to our system crisis; my guess is he may try to give examples of how manufacturers, payers, policy experts, academics, and anybody else in the healthcare system can collaborate and partner to overcome major obstacles regarding healthcare reform. 

Who will give the plenary address? 

Our plenary will be given by Stéphane Thiroloix, CEO of Mayoly Spindler, on the morning of Thurs., Sept. 8. Mayoly Spindler is an emerging family-owned, independent French company, originally founded by a husband-and-wife team working to provide gastroenterology and dermatology healthcare solutions. Stéphane joined as managing director in 2014, and he has lots of leadership experience from working in multiple biopharma executive roles before joining Mayoly Spindler. He is an advocate who understands what it takes to be successful in a partnership and basically created the partnership management function in his last two roles.  He will share what a CEO’s expectations are for alliance management success. 

To view the program and download brochure information, go to www. asapweb.org/biopharma.

Tags:  alliance management  biopharma  collaborate  Dr. Samuel Nussbaum  ecosystem  healthcare  healthcare reform  Mayoly Spindler  partner  partnership  Partnership management  Partnerships  public policy  Stéphane Thiroloix  tech 

Share |
PermalinkComments (0)
 
Page 11 of 15
 |<   <<   <  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15
For more information email us at info@strategic-alliances.org or call +1-781-562-1630